CoChat

Microphysiological systems as models for immunologically ‘cold’ tumors

Open access
Gaebler, Daniela, Hachey, Stephanie J., Hughes, Christopher C. W. · 2024 · Frontiers in Cell and Developmental Biology

The DOI matches its Crossref record; 206 of the 210 references it cites were found in a registry or an index; 210 of the 287 sources its claims cite were checked for support.

Abstract

The tumor microenvironment (TME) is a diverse milieu of cells including cancerous and non-cancerous cells such as fibroblasts, pericytes, endothelial cells and immune cells. The intricate cellular interactions within the TME hold a central role in shaping the dynamics of cancer progression, influencing pivotal aspects such as tumor initiation, growth, invasion, response to therapeutic interventions, and the emergence of drug resistance. In immunologically ‘cold’ tumors, the TME is marked by a scarcity of infiltrating immune cells, limited antigen presentation in the absence of potent immune-stimulating signals, and an abundance of immunosuppressive factors. While strategies targeting the TME as a therapeutic avenue in ‘cold’ tumors have emerged, there is a pressing need for novel approaches that faithfully replicate the complex cellular and non-cellular interactions in order to develop targeted therapies that can effectively stimulate immune responses and improve therapeutic outcomes in patients. Microfluidic devices offer distinct advantages over traditional in vitro 3D co-culture models and in vivo animal models, as they better recapitulate key characteristics of the TME and allow for precise, controlled insights into the dynamic interplay between various immune, stromal and cancerous cell types at any timepoint. This review aims to underscore the pivotal role of microfluidic systems in advancing our understanding of the TME and presents current microfluidic model systems that aim to dissect tumor-stromal, tumor-immune and immune-stromal cellular interactions in various ‘cold’ tumors. Understanding the intricacies of the TME in ‘cold’ tumors is crucial for devising effective targeted therapies to reinvigorate immune responses and overcome the challenges of current immunotherapy approaches.

Overview

CoChat Summary

TL;DR

This review argues that microphysiological systems (MPS)/tumor chips can better model immunologically ‘cold’ tumors than traditional 2D or animal models by recapitulating tumor-stromal, tumor-immune, and immune-stromal interactions. It surveys MPS for ovarian, pancreatic, renal, and prostate cancers and concludes the field is nascent, with few models incorporating full vasculature and immune complexity.

Key findings

  • Immunologically ‘cold’ tumors are characterized by immune exclusion or exhaustion, desmoplastic stroma, poor perfusion/hypoxia, and enrichment of immunosuppressive cells such as Tregs, M2 TAMs, MDSCs, and CAFs; fewer than 15% of patients respond to immune checkpoint inhibitor therapy.
  • MPS can reproduce key TME features: a vascularized micro-tumor model enables de novo perfusable microvascular networks and T-cell extravasation; ovarian PDX spheroids show enhanced formation, proliferation, and viability under microfluidic conditions compared with larger-scale 3D cultures or Matrigel; sequential fibroblast addition to ovarian spheroids yields the highest vascularization, and CAR T cells are recruited, extravasate, and produce a strong IFN-γ response.
  • In PDAC, endothelial cells significantly reduce T-cell infiltration while pancreatic stellate cells increase it; activated T cells show a 50% increase in migration toward cancer cells. In RCC, high-density collagen limits CAR-T cell infiltration; in prostate, LNCaP versus C-2 cells polarize macrophages toward M1 versus M2 phenotypes and alter endothelial networks.
  • The review cites disease-burden figures including about 20,000 new ovarian cancer cases and more than 12,000 deaths in 2024; PDAC median survival under 6 months and 5-year survival below 4%; metastatic RCC 5-year survival under 12%; and prostate cancer projected to claim more than 35,000 lives this year.

Methods

  • Narrative review; no primary experiments are reported. It synthesizes published microfluidic/tumor-chip studies for immunologically ‘cold’ tumors, focusing on ovarian cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, and prostate cancer.
  • Tables 1–4 summarize selected MPS by cancer model, key device features, cell types, and key findings.
  • The main analysis is qualitative synthesis of device designs, cellular components, and reported outcomes; no systematic search strategy or meta-analysis is described.

Limitations

  • Stated in the paper: few MPS exist for immunologically ‘cold’ tumors, especially those focusing on T-cell modulation; many models lack essential cellular and acellular TME components, physiologically relevant vascularization, and complex cellular crosstalk.
  • Stated in the paper: adoption faces challenges including limited cell sourcing, accessibility to non-expert users, regulatory approvals for precision medicine use, and difficulties with intricate biofabrication protocols and throughput.
  • Evident from the text: as a narrative review, it does not report a systematic search, inclusion criteria, or quantitative synthesis, so conclusions depend on the cited studies and are not independently validated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fcell.2024.1389012

Cites

206 of 206 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Tumor microenvironments characterized as immunologically ‘cold’ exhibit distinct features. In the upper panel, ‘cold’ tumors are often less vascularized, presenting abnormal vasculature with lack of tight endothelial junctions, inadequate pericyte coverage, increased permeability and poor perfusion. The infiltration of T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs) and M2 polarized macrophages is prevalent in ‘cold’ tumors, as are cancer-associated fibroblasts (CAFs), while cytotoxic CD8+ T cells, natural killer (NK) cells, dendritic cells (DCs) and M1 macrophages are relatively excluded and/or exhausted. In contrast, ‘hot’ tumors exhibit an opposite phenotype, demonstrating responsiveness to immunotherapy and resulting in cancer cell death. The lower panel illustrates various mechanisms through which ‘cold’ tumors dysregulate immune function within the tumor TME.
FIGURE 1 Tumor microenvironments characterized as immunologically ‘cold’ exhibit distinct features. In the upper panel, ‘cold’ tumors are often less vascularized, presenting abnormal vasculature with lack of tight endothelial junctions, inadequate pericyte coverage, increased permeability and poor perfusion. The infiltration of T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs) and M2 polarized macrophages is prevalent in ‘cold’ tumors, as are cancer-associated fibroblasts (CAFs), while cytotoxic CD8+ T cells, natural killer (NK) cells, dendritic cells (DCs) and M1 macrophages are relatively excluded and/or exhausted. In contrast, ‘hot’ tumors exhibit an opposite phenotype, demonstrating responsiveness to immunotherapy and resulting in cancer cell death. The lower panel illustrates various mechanisms through which ‘cold’ tumors dysregulate immune function within the tumor TME.CC BY · PubMed Central
FIGURE 2 Tumor chips to model immunologically ‘cold’ tumors. (A). The vascularized micro-tumor (VMT) is a physiologically relevant tumor chip model. Platform assembly features a PDMS layer with 12 device units bonded to a bottomless 96-well plate, sealed with a transparent polymer membrane. Vascular networks are fully perfused and can be used for onco-immunology studies by perfusing cancer cells and/or T cells. Adapted from Hachey et al. (2023a). (B). (A) Microfluidic co-culture model of ovarian tumor cells and endothelial cells enabling the extravasation of platelets. Treatment with atorvastatin limits platelet extravasation though improvement of vessel barrier function (B) and endothelial gaps (C), which is accompanied by changes in the expression of major inflammatory cytokines (D). Adapted from Saha et al. (2020). (C). (Ai) Schematic overview of the interactional dynamics between extravasating neutrophils and pre-metastatic ovarian tumor cells (Aii) Schematic conceptulization of the TIME in the microfluidic device (B) Assembly of microfluidic dish platform to create TIME-on-a-chip. Adapted from Surendran et al. (2021). (D). (A) Microfluidic co-culture model design featuring PDAC tumor cells (Panc1) and macrophages with the inclusion of interstitial flow (IF). Representative confocal image of gel channels seeded with cells at 0 h, (B) depicting tumor cells, and (C) without tumor cells. Adapted from Lee et al. (Lee et al., 2020). (E). Microfluidic system that allows individually prepared cell layers (A) to be vertically stacked (B) to study complex multicellular interactions. (C) Co-culture of endothelial cells and fibroblasts leads to the formation of micro-vessels (D) The multiculture of endothelial-fibroblast (bottom layer) and macrophages (upper layer) resulted in abnormal vessel morphology. Adapted from Yu et al. (2019).
FIGURE 2 Tumor chips to model immunologically ‘cold’ tumors. (A). The vascularized micro-tumor (VMT) is a physiologically relevant tumor chip model. Platform assembly features a PDMS layer with 12 device units bonded to a bottomless 96-well plate, sealed with a transparent polymer membrane. Vascular networks are fully perfused and can be used for onco-immunology studies by perfusing cancer cells and/or T cells. Adapted from Hachey et al. (2023a). (B). (A) Microfluidic co-culture model of ovarian tumor cells and endothelial cells enabling the extravasation of platelets. Treatment with atorvastatin limits platelet extravasation though improvement of vessel barrier function (B) and endothelial gaps (C), which is accompanied by changes in the expression of major inflammatory cytokines (D). Adapted from Saha et al. (2020). (C). (Ai) Schematic overview of the interactional dynamics between extravasating neutrophils and pre-metastatic ovarian tumor cells (Aii) Schematic conceptulization of the TIME in the microfluidic device (B) Assembly of microfluidic dish platform to create TIME-on-a-chip. Adapted from Surendran et al. (2021). (D). (A) Microfluidic co-culture model design featuring PDAC tumor cells (Panc1) and macrophages with the inclusion of interstitial flow (IF). Representative confocal image of gel channels seeded with cells at 0 h, (B) depicting tumor cells, and (C) without tumor cells. Adapted from Lee et al. (Lee et al., 2020). (E). Microfluidic system that allows individually prepared cell layers (A) to be vertically stacked (B) to study complex multicellular interactions. (C) Co-culture of endothelial cells and fibroblasts leads to the formation of micro-vessels (D) The multiculture of endothelial-fibroblast (bottom layer) and macrophages (upper layer) resulted in abnormal vessel morphology. Adapted from Yu et al. (2019).CC BY · PubMed Central

Verification

Claims the paper makes

159 Valid · 15 Not valid · 45 Not checked · 42 Own results and interpretations

120 more claims · 66 with their cited sources checked

Create a free account to see all 261 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 121
  • Probably not a substantial claim. 32

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 206 references

Research works printed but not linked: 1

  1. Bonaventura P. Shekarian T. Alcazer V. Valladeau-Guilemond J. Valsesia-Wittmann S. Amigorena S. (2019b). Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168. 10.3389/fimmu.2019.00168 30800125 PMC6376112 · DOI · Paper page

Cited by

Metadata

Authors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W.
Affiliations
University of California, Irvine (US)
Corresponding author
Hughes, Christopher C. W.
Venue
Frontiers in Cell and Developmental Biology
Published
2024-04-22
Volume
12
Pages
1389012-1389012
ISSN
2296-634X (ISSN-L)
OpenAlex
W4395006996
Cited by
14
References
210
Citations by year
2026: 7 · 2025: 6 · 2024: 1
FWCI
0.45
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Institutes of Health
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
Keywords
microphysiological systems, cold tumors, tumor microenvironment, microfluidics, tumor-stroma interactions, tumor-immune interactions, cancer immunotherapy, immunosuppression, 3D co-culture model, drug resistance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.